Innovative Pharmaceutical Biotech Dirección

Dirección controles de criterios 2/4

We currently do not have sufficient information about the CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	8.9yrs
Promedio de permanencia en la Junta Directiva	13yrs

Actualizaciones recientes de la dirección

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

CEO

Innovative Pharmaceutical Biotech no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rong Tang	Executive Director	10.2yrs	HK$548.00k	0.022% HK$ 79.2k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	sin datos
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	sin datos
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	4.2yrs	sin datos	28.87% HK$ 105.2m
Hon Yin Poon	Financial Controller & Company Secretary	11.5yrs	sin datos	sin datos
Qi Dong	Sales Head of the Group	no data	sin datos	sin datos
Wei Yu	Joint Chairman to the Department of Innovation & Strategic Development and Advisor	no data	sin datos	sin datos
Jie Gu	Adviser and Joint Chairman to the Department of Innovation & Strategic Development	8.9yrs	sin datos	sin datos
Yi Xie	Chief Executive of United Gane Holdings Limited	no data	sin datos	sin datos
Dong Hui	General Manager of the Group and Director of CJV	no data	sin datos	sin datos

8.9yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: 399's management team is seasoned and experienced (8.9 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rong Tang	Executive Director	10.2yrs	HK$548.00k	0.022% HK$ 79.2k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	sin datos
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	sin datos
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	14.2yrs	sin datos	28.87% HK$ 105.2m
Dong Hui	General Manager of the Group and Director of CJV	no data	sin datos	sin datos
Chung Lau	Director of CJV	no data	sin datos	sin datos
Weijun Chen	Independent Non-Executive Director	15yrs	HK$80.00k	sin datos
Nian Jiang	Non Executive Chairman	13.9yrs	HK$60.00k	sin datos
Yanmin Wu	Non-Executive Director	13.4yrs	HK$60.00k	sin datos
Rongliang Wang	Independent Non-Executive Director	13.4yrs	HK$60.00k	sin datos
Yan Xiao	Non-Executive Director	12.5yrs	HK$60.00k	sin datos
Jinzhong Chen	Independent Non-Executive Director	3.8yrs	HK$60.00k	sin datos

13.0yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: 399's board of directors are seasoned and experienced ( 13 years average tenure).

Innovative Pharmaceutical Biotech Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Less than half of directors are independent

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

New minor risk - Share price stability

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad